PixCell Medical

Executive Summary

PixCell Medical is an Israeli med-tech company that has developed HemoScreen, a portable point-of-care complete blood count (CBC) analyzer. The device leverages patented Viscoelastic Focusing microfluidics and AI-driven image analysis to deliver lab-grade hematology results in five minutes from a finger-stick or venous sample. Targeting primary care, emergency medicine, oncology, pediatrics, blood banks, and military settings, HemoScreen addresses the critical need for rapid, decentralized blood testing. The company was founded in 2020 and has reached the commercial stage, though specific funding and sales data are not disclosed. Its technology has the potential to disrupt traditional hematology by reducing turnaround times and enabling diagnostic access in remote or resource-limited environments.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation HemoScreen70% success
• Q4 2026Strategic partnership with a major diagnostics distributor60% success
• Q2 2026Publication of clinical validation study in a peer-reviewed journal80% success